Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F13%3A%230000413" target="_blank" >RIV/00209805:_____/13:#0000413 - isvavai.cz</a>
Result on the web
<a href="http://www.nature.com/onc/journal/v32/n20/full/onc2012346a.html" target="_blank" >http://www.nature.com/onc/journal/v32/n20/full/onc2012346a.html</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/onc.2012.346" target="_blank" >10.1038/onc.2012.346</a>
Alternative languages
Result language
angličtina
Original language name
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development
Original language description
Clinical studies have defined the core 'genetic blueprint' of a cancer cell, but this information does not necessarily predict the cancer phenotype. Signalling hubs that mediate such phenotype have been identified largely using OMICS platforms that measure dynamic molecular changes within the cancer cell landscape. The pro-oncogenic protein anterior gradient 2 (AGR2) is a case in point; AGR2 has been shown using a range of expression platforms to be involved in asthma, inflammatory bowel disease, cell transformation, cancer drug resistance and metastatic growth. AGR2 protein is also highly overexpressed in a diverse range of human cancers and can be secreted and detected in extracellular fluids, thus representing a compelling pro-oncogenic signalling intermediate in human cancer. AGR2 belongs to the protein disulphide isomerase family with all the key features of an endoplasmic reticulum-resident protein-this gives clues into how it might function as an oncoprotein through the regulati
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncogene
ISSN
0950-9232
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
20
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
2499-2509
UT code for WoS article
000319274300001
EID of the result in the Scopus database
—